KU Leuven
Mattijs Bulcaen, MSc, is a passionate young biochemist and PhD researcher from KU Leuven, Belgium. In 2020 he graduated among the top of his class and has ever since demonstrated an unwavering commitment to scientific excellence and propelling the field of Cystic Fibrosis (CF) gene therapy forward. His research, guided by esteemed mentors Prof. Dr. M. Carlon and Prof. Dr. Z. Debyser, focuses on gene editing strategies aimed at overcoming drug-refractory CFTR mutations causing CF. He received additional training with leading global experts in CF and gene editing such as Prof. Dr. Isabelle Sermet at Université Cité Paris, France and Prof. Dr. Matthew Porteus at Stanford University, CA, USA.
Mr. Bulcaen completed his Bachelor's and Master’s degrees in Biochemistry and Biotechnology at KU Leuven with highest honors: summa cum laude with congratulations of the examination committee. For his bachelor thesis, mr. Bulcaen worked together with prof. J. Robben on the characterization on the Mrr endonuclease found in E. coli, within hindsight a project that could be considered “bacterial gene editing”. He combined his undergrad studies with a variety of extracurricular activities including an industry internship at the stem-cell focussed biotech ReGenesys, roles as student representative and PAL tutor for Molecular Biology, as well as the role of bio-assay team leader for the KU Leuven 2019 delegation in the SensUs international student competition. For his Master’s thesis, mr. Bulcaen joined the CF group of Prof. Dr. Marianne Carlon with the aim to develop gene editing approaches for drug-refractory CFTR mutations.
Even before graduating, his academic excellence and team-minded spirit were recognized with several awards, including the KVCV Award for the most meritorious student in Chemistry and Biochemistry. His involvement in the SensUs competition, where his team won the Translational Potential Award as well as bronze medals for Analytical Performance and Public Inspiration, highlighted his ability to lead and innovate in a collaborative, multidisciplinary setting. As the bio-assay team leader, he played a crucial role in developing the biosensor prototype, showcasing his skills in experimental design, data interpretation, and practical application of biochemistry.
In 2020, dr. Bulcaen commenced his doctoral training in the laboratory for Molecular Virology and Gene Therapy at KU Leuven where his research focuses on gene editing approaches to develop potential curative strategies for CF. His work involves cutting-edge technologies like CRISPR, base editing, and prime editing, combined with innovative delivery vehicles (VLPs, LNPs) for testing in complex, patient-derived models including 3D organoids and differentiated airway cultures. His dedication to this research is driven by a desire to make a tangible impact on the lives of those affected by CF, especially those who’s symptoms can not be relieved through established modulator therapies.
In 2021, dr. Bulcaen was awarded a prestigious FWO fellowship for Strategic Basic Research, which provides substantial funding for his research. This fellowship is highly competitive, with a rigorous selection process that includes public defense of his research plan and personal motivation. His doctoral journey has been marked by additional achievements, including the prestigious ECFS Young Investigator Award in 2022, numerous conference awards, an Emily’s Entourage research award and an FWO long stay travel grant award to join the lab of dr. Matthew Porteus at Stanford University. The recognition he has garnered through awards and grants is a testimony for his enthousiasm and dedication for CF research.
His early yet significant contributions to the scientific community are reflected in the publication record he was able to put together during the past four years. He has authored and co-authored several papers and perspectives in high-impact journals, including a book chapter on rewriting CFTR to cure CF and articles on prime editing in human organoids and airway epithelial cells. His research has provided important proof of principle for correction of drug-refractory CFTR mutations and was the first to evidence prime editing in primary epithelial cells, offering new hope for treatments of genetic diseases like CF.
In addition to his technical and academic achievements, Mr. Bulcaen is known for his strong belief in teamwork and collaboration. During his PhD, he mentored eigth students with Bachelor, Master or PhD levels in Biochemistry, Biomedical Sciences and Bioinformatic and is always ready to assist his peers and contribute to collective efforts, understanding that the best scientific advances often come from working together. His role as a PAL tutor for Molecular Biology and, student representative at KU Leuven and success as bio-assay team lead for Sensus demonstrate his ability to manage and motivate a diverse group of individuals toward a common goal. His experience in these roles has equipped him with valuable skills in communication, project management, and interdisciplinary collaboration and also exemplifies his willingness to supporting and guiding others.
Mr. Bulcaen’s commitment to excellence extends beyond his research. He is fluent in multiple languages, proficient in bioinformatics, various digital tools, and highly skilled in a wide range of biochemical and molecular techniques. His ability to efficiently manage his time and resources ensures that he maximizes the impact of his work, always striving for the highest quality and efficiency in his research projects.
At NACFC 2024 in Boston, dr. Bulcaen will present his latest results on efficient and transient gene editing approaches for CF in session RFPT01.
Thursday, September 26, 2024
9:00 AM – 9:50 AM ET